Ann Jeanine Greving Brown, LCSW | |
811 L Rd, Chapman, NE 68827-2744 | |
(308) 946-3950 | |
(308) 946-3950 |
Full Name | Ann Jeanine Greving Brown |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | 811 L Rd, Chapman, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407939168 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 573 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ann Jeanine Greving Brown, LCSW Po Box 36, Chapman, NE 68827-0036 Ph: (308) 946-3950 | Ann Jeanine Greving Brown, LCSW 811 L Rd, Chapman, NE 68827-2744 Ph: (308) 946-3950 |
News Archive
Biotheranostics, Inc. announces new data from studies for both of its proprietary molecular diagnostic tests, CancerTYPE ID and Breast Cancer Index to be presented on Saturday, June 2nd and Monday, June 4th at the annual meeting of the American Society of Clinical Oncology in Chicago.
Soo Young Lee and colleagues, at Ewha Womans University, Republic of Korea, have developed a cell-permeable inhibitor of the mouse protein RANK (which they termed RRI) that is likely to aid in the development of selective drugs to treat diseases that involve substantial bone loss, for example, osteoporosis, periodontitis, and arthritis.
Boston Scientific Corporation announces the U.S. launch of its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures.
Most adolescent survivors of childhood cancer have no reported psychological symptoms, but an analysis led by St. Jude Children's Research Hospital found that those who do often have multiple symptoms and distinct symptom profiles.
VaxInnate Corporation today announced that enrollment has commenced in a Phase I clinical trial to evaluate VAX161, its novel H5 vaccine candidate in development for the prevention of pandemic avian influenza or bird flu. VaxInnate is a biotechnology firm pioneering breakthrough technology for developing novel vaccines.
› Verified 6 days ago